Literature DB >> 25041596

Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study.

N Patel1, N Alkhouri, K Eng, F Cikach, L Mahajan, C Yan, D Grove, E S Rome, R Lopez, R A Dweik.   

Abstract

BACKGROUND: Breath testing is becoming an important diagnostic method to evaluate many disease states. In the light of rising healthcare costs, is important to develop a simple non-invasive tool to potentially identify paediatric patients who need endoscopy for suspected inflammatory bowel disease (IBD). AIM: To analyse exhaled volatile organic compounds (VOCs) and investigate the presence of a unique breath patterns to differentiate paediatric patients with (IBD) from healthy controls.
METHODS: A cross-sectional, single-centre study included paediatric IBD patients and healthy controls (age range, 5-21 years). The diagnosis of IBD was confirmed by endoscopic, histological and radiographic data. Exhaled breath was collected and analysed using a selective ion flow tube mass spectroscopy (SIFT-MS) to identify new markers or patterns of IBD.
RESULTS: One hundred and seventeen patients (62 with IBD and 55 healthy controls) were included in the study. Linear discriminant analysis and principle component analysis of mass scanning ion peak data demonstrated 21 pre-selected VOCs correctly classify patients with IBD or as healthy controls; P < 0.0001. Multivariable logistic regression analysis further showed three specific VOCs (1-octene, 1-decene, (E)-2-nonene) had excellent accuracy for predicting the presence of IBD with an area under the curve (AUC) of 0.96 (95% CI: 0.93-0.99). No significant difference in VOCs was found between patients with Crohn's disease or ulcerative colitis, and no significant correlation was seen with disease activity.
CONCLUSION: These pilot data support the hypothesis that a unique breathprint potentially exists for paediatric IBD in the exhaled metabolome.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25041596      PMCID: PMC4127094          DOI: 10.1111/apt.12861

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  26 in total

1.  Variation in volatile organic compounds in the breath of normal humans.

Authors:  M Phillips; J Herrera; S Krishnan; M Zain; J Greenberg; R N Cataneo
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-06-11

2.  A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease.

Authors:  Ramesh P Arasaradnam; Nathalie Ouaret; Matthew G Thomas; Nabil Quraishi; Evelyn Heatherington; Chuka U Nwokolo; Karna D Bardhan; James A Covington
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

3.  Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer.

Authors:  Sacheen Kumar; Juzheng Huang; Nima Abbassi-Ghadi; Patrik Španěl; David Smith; George B Hanna
Journal:  Anal Chem       Date:  2013-05-29       Impact factor: 6.986

Review 4.  Mass spectrometry for real-time quantitative breath analysis.

Authors:  David Smith; Patrik Španěl; Jens Herbig; Jonathan Beauchamp
Journal:  J Breath Res       Date:  2014-03-28       Impact factor: 3.262

Review 5.  Review article: next generation diagnostic modalities in gastroenterology--gas phase volatile compound biomarker detection.

Authors:  R P Arasaradnam; J A Covington; C Harmston; C U Nwokolo
Journal:  Aliment Pharmacol Ther       Date:  2014-02-20       Impact factor: 8.171

Review 6.  Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis.

Authors:  David Smith; Patrik Spanel
Journal:  Mass Spectrom Rev       Date:  2005 Sep-Oct       Impact factor: 10.946

7.  Exhaled breath analysis: The new interface between medicine and engineering.

Authors:  Alquam Mashir; Raed A Dweik
Journal:  Adv Powder Technol       Date:  2009-09       Impact factor: 4.833

8.  Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases.

Authors:  Christopher Walton; Dawn P Fowler; Claire Turner; Wenjing Jia; Rebekah N Whitehead; Lesley Griffiths; Claire Dawson; Rosemary H Waring; David B Ramsden; Jeffrey A Cole; Michael Cauchi; Conrad Bessant; John O Hunter
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

9.  Single exhaled breath metabolomic analysis identifies unique breathprint in patients with acute decompensated heart failure.

Authors:  Michael A Samara; W H Wilson Tang; Frank Cikach; Zeynep Gul; Lily Tranchito; Kelly M Paschke; Jamie Viterna; Yuping Wu; Daniel Laskowski; Raed A Dweik
Journal:  J Am Coll Cardiol       Date:  2013-04-02       Impact factor: 24.094

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  21 in total

1.  Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Betty K Hamilton; Lisa A Rybicki; David Grove; Christina Ferraro; Jamie Starn; Brittany Hodgeman; Jamie Elberson; Victoria Winslow; Donna Corrigan; Aaron T Gerds; Rabi Hanna; Matt E Kalaycio; Ronald M Sobecks; Navneet S Majhail; Raed A Dweik
Journal:  Blood Adv       Date:  2019-09-24

Review 2.  Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Authors:  Jarrod W Barnes; Adriano R Tonelli; Gustavo A Heresi; Jennie E Newman; Noël E Mellor; David E Grove; Raed A Dweik
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 3.  Utility of Biomarkers in the Management of Inflammatory Bowel Disease.

Authors:  Gursimran Kochhar; Bret Lashner
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 4.  Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches.

Authors:  R Balfour Sartor; Gary D Wu
Journal:  Gastroenterology       Date:  2016-10-18       Impact factor: 22.682

Review 5.  New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.

Authors:  Edward L Barnes; Robert Burakoff
Journal:  Inflamm Bowel Dis       Date:  2016-12       Impact factor: 5.325

6.  The path towards microbiome-based metabolite treatment.

Authors:  Jotham Suez; Eran Elinav
Journal:  Nat Microbiol       Date:  2017-05-25       Impact factor: 17.745

7.  Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.

Authors:  Aze Wilson; Wendy A Teft; Bridget L Morse; Yun-Hee Choi; Sarah Woolsey; Marianne K DeGorter; Robert A Hegele; Rommel G Tirona; Richard B Kim
Journal:  Dig Dis Sci       Date:  2015-07-10       Impact factor: 3.199

Review 8.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

9.  Exhaled volatile organic compounds analysis in clinical pediatrics: a systematic review.

Authors:  Rosa A Sola Martínez; José M Pastor Hernández; Óscar Yanes Torrado; Manuel Cánovas Díaz; Teresa de Diego Puente; María Vinaixa Crevillent
Journal:  Pediatr Res       Date:  2020-09-12       Impact factor: 3.756

Review 10.  Are Volatile Organic Compounds Accurate Markers in the Assessment of Colorectal Cancer and Inflammatory Bowel Diseases? A Review.

Authors:  Filippo Vernia; Marco Valvano; Stefano Fabiani; Gianpiero Stefanelli; Salvatore Longo; Angelo Viscido; Giovanni Latella
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.